Protagenic Therapeutic -CW25PTIXWPreferred / convertible
13F holders, Q2 2024 (June 30)4holders +2
2new positions
0sold out
$0.01avg. 13F price*
At the end of Q2 2024, 4 institutions reported holding Protagenic Therapeutic -CW25 (PTIXW) in their 13F filings, up 2 from Q1 2024. 2 opened new positions and 0 sold out. The largest holders were Warberg Asset Management LLC ($1K), Susquehanna International Group, LLP ($218) and GTS Securities LLC ($202).
- Company
- Protagenic Therapeutic -CW25
- CUSIP
- 74365N111
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $219 |
| Exits | 0 | $0 |
All 13F filers, Q1 2024 → Q2 2024: 26,700 shares bought and 100 shares sold, net +26,600 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Warberg Asset Management LLC | — | No change | 177,196 | $1K |
| Susquehanna International Group, LLP | — | New | 26,600 | $218 |
| GTS Securities LLC | — | Reduce -0.4% | 25,300 | $202 |
| Bank of America Corp. | — | New | 100 | $1 |
"% of holder's portfolio" is PTIXW's weight in each manager's 13F, not the share of Protagenic Therapeutic -CW25 the manager owns.